Concordance between PD-L1 assays 28-8 and SP263 and their respective scoring algorithms in procured upper gastrointestinal adenocarcinoma samples. This is an ASCO Meeting Abstract from the 2025 ASCO ...

By staying abreast of signs and risk factors, such as persistent indigestion, unexplained weight loss, or discomfort in the abdomen, individuals can take action and receive timely medical advice.

The Gastric Cancer Registry: A multi-omic cellular and molecular resource for cancer biomarker and therapeutic discovery. This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal Cancers ...

Adults with primary primary appendiceal adenocarcinoma face a higher risk of developing a second primary cancer, including ...

The addition of lenvatinib and pembrolizumab to chemotherapy did not extend OS for certain patients with advanced ...

The phase 3 CheckMate 649 trial showed that nivolumab plus chemotherapy significantly improved long-term overall survival in ...

The unsuccessful Phase III results are the latest to suggest that the blockbuster cancer drug is finally bumping up against ...